Tag Archive for: exagamglogene autotemcel

FDA flags off-target effects of Vertex, CRISPR’s sickle cell therapy ahead of adcomm

In a briefing document for Tuesday’s advisory committee meeting, the FDA raised concerns about the potential off-target effects of Vertex Pharmaceuticals and CRISPR Therapeutics’ investigational gene edited therapy.

Read more
/by

Gene editing race between Editas and Vertex, CRISPR heats up

,

Data show the potential of Editas’ sickle cell disease and transfusion-dependent beta thalassemia gene therapy candidate, but it might not be enough to overtake Vertex and CRISPR Therapeutics.

Read more
/by